Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2021 | Immunotherapy updates from WCLC 2021

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, shares his key takeaways from the WCLC 2021. He highlights KEYNOTE-010 trial (NCT01905657) of pembrolizumab versus docetaxel in NSCLC which had long-term follow-up results presented at the conference. Other immunotherapies also stood out, including neoadjuvant atezolizumab in the LCMC3 trial (NCT02927301) and nivolumab, trialed against placebo in the landmark CONFIRM study (NCT03063450) of advanced mesothelioma. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.


Honoraria: Amgen, AstraZeneca, Boehringer-Ingelheim, BMS, Lilly, Mirati, Merck, Novartis, Pfizer, Regeneron, Roche.